We are live on ! Find out more
GT

Glenmede Trust Portfolio holdings

AUM $20.4B
This Fund
S&P 500
This Quarter Est. Return
+6.16%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$25B
AUM Growth
+$2.37B
Cap. Flow
+$1.17B
Cap. Flow %
4.67%
Top 10 Hldgs %
16.34%
Holding
2,152
New
227
Increased
430
Reduced
632
Closed
714

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$804M
2
ACN icon
Accenture
ACN
+$118M
3
SYY icon
Sysco
SYY
+$76.9M
4
AAPL icon
Apple
AAPL
+$76.7M
5
NTAP icon
NetApp
NTAP
+$69.1M

Sector Composition

Rank Sector Weight
1 Technology 16.58%
2 Healthcare 13.03%
3 Financials 12.46%
4 Consumer Discretionary 10.73%
5 Industrials 9.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CASS icon
1076
Cass Information Systems
CASS
$705M
$124K ﹤0.01%
2,303
NAB
1077
DELISTED
NATL AUSTRALIA BK LTD ADS5
NAB
$124K ﹤0.01%
12,381
-2,735
-18% -$27.4K
SAN icon
1078
Banco Santander
SAN
$200B
$121K ﹤0.01%
25,304
-1,826
-7% -$9.19K
AMRX icon
1079
Amneal Pharmaceuticals
AMRX
$5.78B
$120K ﹤0.01%
5,479
-184
-3% -$3.87K
ADAP
1080
DELISTED
Adaptimmune Therapeutics
ADAP
$119K ﹤0.01%
8,823
MATX icon
1081
Matsons
MATX
$6.22B
$119K ﹤0.01%
3,011
C.PRJ
1082
DELISTED
CITIGROUP INC. Depositary Shares, Each Representing a 1/1,000th Interest in a Share of 7.125% Fixed Rate / Floating Rate Noncumulative Preferred Stock, Series J
C.PRJ
$118K ﹤0.01%
4,237
+1,500
+55% +$42.1K
VYX icon
1083
NCR Voyix
VYX
$1.13B
$117K ﹤0.01%
6,763
-1,332
-16% -$23.7K
VRSK icon
1084
Verisk Analytics
VRSK
$27.1B
$116K ﹤0.01%
969
-395
-29% -$46K
GG
1085
DELISTED
Goldcorp Inc
GG
$115K ﹤0.01%
11,352
-167
-1% -$1.96K
NEO icon
1086
NeoGenomics
NEO
$1.71B
$114K ﹤0.01%
+7,525
New +$104K
FLG
1087
Flagstar Bank National Association
FLG
$5.74B
$114K ﹤0.01%
+3,686
New +$121K
SHG icon
1088
Shinhan Financial Group
SHG
$33.6B
$111K ﹤0.01%
+2,800
New +$108K
AFG icon
1089
American Financial Group
AFG
$12B
$110K ﹤0.01%
1,000
-180
-15% -$20K
RGEN icon
1090
Repligen
RGEN
$7.39B
$110K ﹤0.01%
1,991
-5
-0.3% -$258
CXO
1091
DELISTED
CONCHO RESOURCES INC.
CXO
$109K ﹤0.01%
723
+167
+30% +$23.5K
CHK
1092
DELISTED
Chesapeake Energy Corporation
CHK
$104K ﹤0.01%
116
ANET icon
1093
Arista Networks
ANET
$215B
$103K ﹤0.01%
6,240
+64
+1% +$1.09K
AEH.CL
1094
DELISTED
Aegon NV 6.375% Perpetual Capital Securities Called for Redemption
AEH.CL
$102K ﹤0.01%
4,000
PBI icon
1095
Pitney Bowes
PBI
$2.46B
$101K ﹤0.01%
14,400
CGEN icon
1096
Compugen
CGEN
$225M
$100K ﹤0.01%
26,000
-10,000
-28% -$35K
SPPP
1097
Sprott Physical Platinum and Palladium Trust
SPPP
$577M
$99K ﹤0.01%
+11,375
New +$91.5K
ORMP icon
1098
Oramed Pharmaceuticals
ORMP
$170M
$97K ﹤0.01%
20,000
IRBT
1099
DELISTED
iRobot
IRBT
$91K ﹤0.01%
838
+260
+45% +$24.5K
HWM icon
1100
Howmet Aerospace
HWM
$115B
$89K ﹤0.01%
5,335
+568
+12% +$9.04K

Similar funds

Glenmede Trust's Q3 2018 Portfolio in Review

As of Q3 2018, Glenmede Trust held 2,152 positions worth $25B, up 11% from $22.6B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Glenmede Trust deployed $1.17B of net new capital in Q3 2018, opening 227 new positions and adding to 430 existing holdings. Its largest new stake was Vanguard Small-Cap ETF: 518,651 shares worth $84.3M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $804M trimmed.

  • Glenmede Trust's largest Q3 2018 buy was Vanguard Small-Cap ETF: 518,651 shares worth $84.3M.
  • Glenmede Trust added most to Alphabet (Google) Class A in Q3 2018, an estimated $783M increase.
  • Glenmede Trust's biggest Q3 2018 reduction was Johnson & Johnson, cutting an estimated $804M.
  • Glenmede Trust fully exited BioTelemetry, Inc. in Q3 2018, selling an estimated $43.4M.
  • Glenmede Trust's ten largest holdings make up 16% of its $25B portfolio in Q3 2018.
  • Glenmede Trust opened 227 new positions and closed 714 in Q3 2018.
  • Glenmede Trust's portfolio value rose 11% quarter-over-quarter to $25B.

Based on Glenmede Trust's 13F filing for Q3 2018, filed 15 Nov 2018.